Earnings Feed
Start Free
Home/Filings/4/0001601830-24-000095
4//SEC Filing

Marriott Tina 4

Accession 0001601830-24-000095

CIK 0001601830other
View on SEC.govCompany Profile

Filed

Jun 27, 8:00 PM ET

Accepted

Jun 28, 5:14 PM ET

Size

16.5 KB

Accession

0001601830-24-000095

Insider Transaction Report

Form 4
Period: 2024-06-27
RECURSION PHARMACEUTICALS, INC.RXRX
Larson Tina Marriott
President and COO
Transactions
  • Sale

    Class A Common Stock

    2024-06-27$7.21/sh−6,000$43,290→ 535,457 total
  • Exercise/Conversion

    Class A Common Stock

    2024-06-27$1.06/sh+6,000$6,360→ 541,457 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-06-27−6,000→ 476,000 total
    Exercise: $1.06Exp: 2028-07-22→ Class A Common Stock (6,000 underlying)
Holdings

  • Stock Option (Right to Buy)

    Exercise: $8.55Exp: 2033-02-01→ Class A Common Stock (0 underlying)
    434,122

  • Stock Option (Right to Buy)

    Exercise: $2.48Exp: 2030-12-30→ Class A Common Stock (0 underlying)
    150,000

  • Stock Option (Right to Buy)

    Exercise: $11.40Exp: 2032-02-04→ Class A Common Stock (0 underlying)
    159,226

  • Stock Option (Right to Buy)

    Exercise: $11.40From: 2022-02-04Exp: 2032-02-04→ Class A Common Stock (0 underlying)
    4,784

  • Stock Option (Right to Buy)

    Exercise: $10.09Exp: 2034-02-09→ Class A Common Stock (0 underlying)
    447,917
Footnotes (7)
  • [F1]Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2024.
  • [F2]This transaction was executed in multiple trades at prices ranging from $6.91 to $7.575. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F3]Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
  • [F4]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
  • [F5]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
  • [F6]One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.
  • [F7]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

Documents

1 file

Issuer

RECURSION PHARMACEUTICALS, INC.

CIK 0001601830

→
Entity typeother

Related Parties

1
  • filerCIK 0001856414

Filing Metadata

Form type
4
Filed
Jun 27, 8:00 PM ET
Accepted
Jun 28, 5:14 PM ET
Size
16.5 KB
View on SEC.gov